Boston Scientific Corporation
BSX
株式のランク
#409
この企業概要は英語でのみ提供されています。
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
株価
$41.88
最終同期: 2026-10-30
時価総額
$60.69B
変化（1日）
-1.89%
変化（1年）
-58.42%
国
US
株式データ: Financial Modeling Prep·更新日: ·投資助言ではありません·計算方法
取引 Boston Scientific Corporation (BSX)
カテゴリー
Healthcare
Boston Scientific Corporation（BSX）の収益
Sep 2026 時点の収益 TTM: $21.07B
Boston Scientific Corporation の最新の財務報告によると、現在の収益 (TTM) は $21.07B です。2025 年には $20.07B の収益があり、これは 2024 年の $16.75B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Boston Scientific Corporation の収益履歴（2000 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $21.07B | 4.96% |
| 2025 | $20.07B | 19.87% |
| 2024 | $16.75B | 17.61% |
| 2023 | $14.24B | 12.29% |
| 2022 | $12.68B | 6.68% |
| 2021 | $11.89B | 19.92% |
| 2020 | $9.91B | -7.66% |
| 2019 | $10.74B | 9.28% |
| 2018 | $9.82B | 8.57% |
| 2017 | $9.05B | 7.89% |
| 2016 | $8.39B | 12.16% |
| 2015 | $7.48B | 1.31% |
| 2014 | $7.38B | 3.32% |
| 2013 | $7.14B | -1.46% |
| 2012 | $7.25B | -4.89% |
| 2011 | $7.62B | -2.36% |
| 2010 | $7.81B | -4.67% |
| 2009 | $8.19B | 1.71% |
| 2008 | $8.05B | -3.67% |
| 2007 | $8.36B | 6.85% |
| 2006 | $7.82B | 24.48% |
| 2005 | $6.28B | 11.72% |
| 2004 | $5.62B | 61.80% |
| 2003 | $3.48B | 19.08% |
| 2002 | $2.92B | 9.20% |
| 2001 | $2.67B | 0.34% |
| 2000 | $2.66B | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $48.23B | 128.91% |
US
|
|
| $37.54B | 78.19% |
IE
|
|
| $26.30B | 24.83% |
US
|
|
| $25.84B | 22.63% |
DE
|
|
| $6.51B | -69.09% |
US
|
Boston Scientific Corporationの売上高に関する質問
Boston Scientific Corporationの売上高はどのくらいですか？
2026年9月時点で、Boston Scientific Corporationの直近12か月の売上高は$21.07Bです。
Boston Scientific Corporationの2025年の売上高はどのくらいでしたか？
2025年のBoston Scientific Corporationの売上高は$20.07Bで、2024年（$16.75B）を19.87%上回りました。
Boston Scientific Corporationの売上高は2020年以降どのように推移していますか？
2020年から2025年にかけて、Boston Scientific Corporationの売上高は$9.91Bから$20.07Bになり、年平均で15.16%のプラスとなりました。
Boston Scientific Corporationの売上高は類似企業と比べてどうですか？
Boston Scientific Corporationの売上高は$21.07Bで、上に挙げた類似企業5社のうち1社を上回っています。これらの企業の中で最も高いのはAbbott Laboratoriesで、$48.23Bです。